United States · FDA
FDA approval not reviewed here
Loading research and source information…
Parkinson’s disease · Biological treatment research
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Oct 27, 2026 · Sources last checked Nov 17, 2026
Inclusion Criteria: 1. Men ≥18 years of age or women ≥45 years of age 2. Written informed consent 3. Receiving drug treatment for diagnosis of mild to moderate Parkinson's Disease 4. Modified Hoehn and Yahr stage 1, 2, or 3 5. Diagnosed with Parkinson's Disease for more than 5 years 6. Stable treatment regimen that has not been modified in the 90 days prior to the start of the study 7. No expected addition of symptomatic therapy for at least one year after the start of the study 8. Women of reproductive age must use contraceptive treatment Exclusion Criteria: 1. Drug-induced Parkinsonism 2. Parkinsonism associated with stroke, progressive supranuclear palsy, Lewy body disease, corticobasal degeneration, or multiple system atrophy 3. Major psychiatric comorbidity that prevents ensuring study follow-up 4. History of alcohol or drug use 5. History of brain surgery for Parkinson's Disease 6. Serious complications deemed inappropriate by Principal Investigator 7. Diagnosis of advanced-stage medical conditions (chronic liver injury with Child-Pugh B or higher, chronic obstructive pulmonary disease with Gold C or higher, or heart failure with ejection fraction \<35%) 8. Use of cytostatic drugs 9. Patients with life expectancy \< 6 months 10. Diabetes mellitus with poor metabolic control (HbA1c \> 8%) 11. Active infectious disease requiring medical treatment 12. Use of systemic steroids or immunosuppressive drugs 13. Patients positive for Hepatitis B antigen, Hepatitis C antibody, or HIV antibody 14. Fertile, pregnant, possibly pregnant, or lactating women 15. History of active mesenchymopathies 16. Active malignancy or diagnosis of malignancy in the last 5 years 17. Abnormal laboratory values, including: * AST \>1.5 times Upper Limit of Normal (ULN) (Normal Range: 8 to 48 Units/L) * ALT \>1.5 times ULN (Normal Range: 7 to 55 Units/L) * Bilirubin \>1.5 times ULN (Normal Range: 0.2 to 1.2 mg/dL) * Creatinine \>1.5 times ULN (Normal Range: 0.5 to 1.30 mg/dL) * Hematocrit significantly outside normal range (36% to 54%) * Lymphocytes significantly outside normal range (103 to 4.8 x 103 lymphocytes/μL) * Monocytes significantly outside normal range (200 to 800 lymphocytes/μL) * Neutrophils significantly outside normal range (2.5 x 103 to 7 x 103 lymphocytes/μL) * Erythrocytes significantly outside normal range (4.7 x 106 to 6.1 x 106 lymphocytes/μL) * Platelets significantly outside normal range (150 x 103 to 450 x 103 lymphocytes/μL)
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Randomized Clinical Trial in Parkinson's Disease Patients Using Pluripotent Adipose Stem Cells (PASCs)
registry · NCT06141317 · Structured source fields
Source date: Oct 22, 2026 · Checked: Nov 17, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: COMPLETED. Phase: PHASE1 / PHASE2. Conditions: Parkinson Disease.
Open original sourceParkinson’s disease
See FDA labeling for the approved population and indication; this page covers the trial population only.
FDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
This study has ended. Completion alone does not show that a treatment works.
Read trial record and posted resultsStudy ages: 18 Years to 80 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Costa Rica.
Primary data collection: Jun 23, 2024 (actual). This is not a results-release date.
No results-posting date in this record.
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
No posted registry results are indicated in this source response. This does not establish that no results exist elsewhere.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1